Genpharmasec Limited (BOM:531592)
India
· Delayed Price · Currency is INR 2.120
+0.010 (0.47%)
At close: Jun 9, 2025
Genpharmasec Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2016 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2016 - 2020 |
| Operating Revenue | 337.22 | 304.06 | 255.16 | 273.21 | 213.08 | Upgrade
|
| Revenue | 337.22 | 304.06 | 255.16 | 273.21 | 213.08 | Upgrade
|
| Revenue Growth (YoY) | 10.91% | 19.16% | -6.61% | 28.22% | 29.13% | Upgrade
|
| Cost of Revenue | 295.48 | 242.33 | 233.97 | 265.65 | 192 | Upgrade
|
| Gross Profit | 41.74 | 61.73 | 21.18 | 7.55 | 21.07 | Upgrade
|
| Selling, General & Admin | 9.89 | 9.18 | 6.83 | 3.59 | 2.9 | Upgrade
|
| Other Operating Expenses | 31.21 | 52.09 | 11.67 | 9.18 | 6.23 | Upgrade
|
| Operating Expenses | 49.21 | 61.69 | 18.7 | 12.91 | 9.25 | Upgrade
|
| Operating Income | -7.47 | 0.04 | 2.48 | -5.36 | 11.82 | Upgrade
|
| Interest Expense | -4.35 | -4.09 | -0.56 | - | - | Upgrade
|
| Interest & Investment Income | - | 4.73 | 0.31 | 0.65 | 3.28 | Upgrade
|
| Currency Exchange Gain (Loss) | - | 1.83 | 0.55 | 0.16 | - | Upgrade
|
| Other Non Operating Income (Expenses) | 30.62 | -0 | 0.04 | 0.11 | - | Upgrade
|
| EBT Excluding Unusual Items | 18.8 | 2.51 | 2.82 | -4.43 | 15.1 | Upgrade
|
| Pretax Income | 18.8 | 2.51 | 2.82 | -4.43 | 15.1 | Upgrade
|
| Income Tax Expense | 6.49 | 4.2 | -8.43 | -2.34 | 2.52 | Upgrade
|
| Earnings From Continuing Operations | 12.31 | -1.69 | 11.25 | -2.09 | 12.57 | Upgrade
|
| Minority Interest in Earnings | - | 0.44 | - | - | - | Upgrade
|
| Net Income | 12.31 | -1.26 | 11.25 | -2.09 | 12.57 | Upgrade
|
| Net Income to Common | 12.31 | -1.26 | 11.25 | -2.09 | 12.57 | Upgrade
|
| Net Income Growth | - | - | - | - | 24.57% | Upgrade
|
| Shares Outstanding (Basic) | - | 307 | 277 | 277 | 271 | Upgrade
|
| Shares Outstanding (Diluted) | - | 307 | 277 | 277 | 271 | Upgrade
|
| Shares Change (YoY) | - | 10.96% | - | 2.06% | -46.25% | Upgrade
|
| EPS (Basic) | - | -0.00 | 0.04 | -0.01 | 0.05 | Upgrade
|
| EPS (Diluted) | - | -0.00 | 0.04 | -0.01 | 0.05 | Upgrade
|
| EPS Growth | - | - | - | - | 131.76% | Upgrade
|
| Free Cash Flow | -27.1 | -29.64 | -30.76 | -24.25 | -21.47 | Upgrade
|
| Free Cash Flow Per Share | - | -0.10 | -0.11 | -0.09 | -0.08 | Upgrade
|
| Gross Margin | 12.38% | 20.30% | 8.30% | 2.77% | 9.89% | Upgrade
|
| Operating Margin | -2.22% | 0.01% | 0.97% | -1.96% | 5.55% | Upgrade
|
| Profit Margin | 3.65% | -0.41% | 4.41% | -0.77% | 5.90% | Upgrade
|
| Free Cash Flow Margin | -8.04% | -9.75% | -12.05% | -8.88% | -10.08% | Upgrade
|
| EBITDA | 0.64 | 0.21 | 2.68 | -5.21 | 11.94 | Upgrade
|
| EBITDA Margin | 0.19% | 0.07% | 1.05% | -1.91% | 5.61% | Upgrade
|
| D&A For EBITDA | 8.12 | 0.17 | 0.2 | 0.14 | 0.13 | Upgrade
|
| EBIT | -7.47 | 0.04 | 2.48 | -5.36 | 11.82 | Upgrade
|
| EBIT Margin | -2.22% | 0.01% | 0.97% | -1.96% | 5.55% | Upgrade
|
| Effective Tax Rate | 34.52% | 167.63% | - | - | 16.70% | Upgrade
|
| Revenue as Reported | 367.84 | 310.62 | 256.16 | 274.13 | 216.35 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.